Creative Planning Has $1.38 Million Stock Position in Koninklijke Philips N.V. $PHG

Creative Planning cut its holdings in shares of Koninklijke Philips N.V. (NYSE:PHG) by 6.5% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 57,356 shares of the technology company’s stock after selling 3,956 shares during the period. Creative Planning’s holdings in Koninklijke Philips were worth $1,375,000 at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. Dimensional Fund Advisors LP increased its holdings in Koninklijke Philips by 2.5% during the 1st quarter. Dimensional Fund Advisors LP now owns 4,396,095 shares of the technology company’s stock worth $111,662,000 after purchasing an additional 106,044 shares in the last quarter. HB Wealth Management LLC purchased a new position in shares of Koninklijke Philips during the first quarter valued at approximately $333,000. Oppenheimer Asset Management Inc. grew its holdings in Koninklijke Philips by 15.1% during the second quarter. Oppenheimer Asset Management Inc. now owns 189,720 shares of the technology company’s stock worth $4,549,000 after buying an additional 24,931 shares in the last quarter. Charles Schwab Investment Management Inc. raised its position in Koninklijke Philips by 18.0% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 72,276 shares of the technology company’s stock valued at $1,836,000 after buying an additional 11,018 shares during the last quarter. Finally, Envestnet Asset Management Inc. lifted its stake in Koninklijke Philips by 2.5% during the 2nd quarter. Envestnet Asset Management Inc. now owns 1,351,015 shares of the technology company’s stock valued at $32,397,000 after acquiring an additional 32,663 shares in the last quarter. Institutional investors own 13.67% of the company’s stock.

Koninklijke Philips Trading Up 0.3%

NYSE PHG opened at $28.16 on Friday. The business’s fifty day moving average is $27.90 and its 200-day moving average is $26.21. The company has a debt-to-equity ratio of 0.68, a current ratio of 1.32 and a quick ratio of 0.86. The stock has a market capitalization of $27.12 billion, a price-to-earnings ratio of 140.81, a PEG ratio of 0.76 and a beta of 0.82. Koninklijke Philips N.V. has a one year low of $21.48 and a one year high of $29.54.

Koninklijke Philips (NYSE:PHG) last posted its quarterly earnings data on Tuesday, November 4th. The technology company reported $0.37 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.37. The business had revenue of $5.05 billion during the quarter, compared to the consensus estimate of $4.30 billion. Koninklijke Philips had a net margin of 1.07% and a return on equity of 12.14%. Equities research analysts predict that Koninklijke Philips N.V. will post 1.63 EPS for the current year.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on the stock. Wall Street Zen upgraded shares of Koninklijke Philips from a “hold” rating to a “buy” rating in a research note on Saturday, November 22nd. Weiss Ratings restated a “hold (c-)” rating on shares of Koninklijke Philips in a report on Tuesday. One research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Buy”.

About Koninklijke Philips

Koninklijke Philips N.V. operates as a health technology company in North America, the Greater China, and internationally. The company operates through Diagnosis & Treatment Businesses, Connected Care Businesses, and Personal Health Businesses segments. It also provides diagnostic imaging solutions, includes magnetic resonance imaging, X-ray systems, and computed tomography (CT) systems and software comprising detector-based spectral CT solutions, as well as molecular and hybrid imaging solutions for nuclear medicine; echography solutions focused on diagnosis, treatment planning and guidance for cardiology, general imaging, obstetrics/gynecology, and point-of-care applications; integrated interventional systems, and interventional diagnostic and therapeutic devices to treat coronary artery and peripheral vascular disease.